Inter Partes Review's Day Has Come For Pharma IP Cases

Law360, New York (August 22, 2014, 10:16 AM EDT) -- The Patent Trial and Appeal Board issued its first final written decisions on June 20, 2014, in four inter partes reviews of pharmaceutical-related patents. The four decisions effectively invalidated all 58 of the challenged patent claims spread across four patents owned by Merck & Cie and the South Alabama Medical Science Foundation, both of whom previously accused Italian biotech firm Gnosis SpA of infringement. 


SAMSF owns three of the patents, which are licensed to Merck, which in turn owns the fourth patent generally relating to the active...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.